- Home
- CISS vs RNAZ Comparison
CISS vs RNAZ Comparison
Compare CISS & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CISS | RNAZ |
|---|---|---|
| Founded | 2022 | 2016 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 2.0M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CISS | RNAZ |
|---|---|---|
| Price | $1.23 | $1.67 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 45.8K |
| Earning Date | 05-19-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.06 | $1.63 |
| 52 Week High | $6.06 | $20.99 |
Technical Indicators
Market Signals| Indicator | CISS | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 45.78 | 23.41 |
| Support Level | $0.76 | N/A |
| Resistance Level | $1.89 | $9.37 |
| Average True Range (ATR) | 0.21 | 0.20 |
| MACD | -0.09 | 0.06 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including national and private industrial users, commodity producers, and traders. The company owns and operates a fleet of two dry bulk carriers that transport bulk commodities such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.